BKYI Stock Forecast: BIO-key International, Inc. Price Predictions for 2026-2027
The median 12-month analyst price target for BIO-key International, Inc. is $20. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 55 of 100 as at 21 Nov 2026 — in the upper half.
One number for the whole business
Consensus tells you what everyone already believes. The model scores BIO-key International, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Accruals (92): Reported profit is backed by cash, and the company is not expanding recklessly.
Revisions (20): Analysts have, on balance, been cutting their forecasts.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
BKYI stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on BKYI, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 26 Mar 2021 | Maxim Group | Upgrade | Buy | $6.00 |
| 25 Nov 2020 | Maxim Group | Downgrade | Hold | — |
| 4 Oct 2019 | Maxim Group | Downgrade | Hold | — |
| 16 Aug 2018 | Maxim Group | Maintains | Buy | $5.50 → $5.00 |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for BKYI.
This page is one stock. Monday covers all of them.
BKYI appears in the Radar on the weeks it earns a place.
- Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
- The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and servers
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
BKYI vs the S&P 500
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 20 Nov 2026, BIO-key International, Inc. returned −78.5% against +6.9% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
BKYI analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Financials
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- —
- Price / sales
- 0.6×
- Price / book
- 0.6×
- EV / EBITDA
- —
Cheaper than 75% of US stocks
Cheaper than 82% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- 87.2%
- Operating margin
- −48.5%
- Net margin
- −89.8%
Higher than 95% of US stocks
Higher than 18% of US stocks
Higher than 7% of US stocks
- Return on equity
- −94.7%
- Return on assets
- −21.2%
- Dividend yield
- —
Higher than 14% of US stocks
Higher than 19% of US stocks
Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.
Key statistics
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
BIO-key International, Inc. has a market value of $4.3M and an enterprise value of $2.2M.
Revenue in the twelve months to 30 June 2026: $6.7M. The latest quarter grew 13.1% year on year.
Net income over the same four quarters: −$6.0M, a −90.1% net margin.
Diluted earnings per share, trailing twelve months: −$4.11.
Free cash flow in the twelve months to 30 June 2026: −$4.2M, after $6K of capital spending.
forward P/E: 9.3× — the forward figure prices analyst consensus estimates, not reported earnings.
BIO-key International, Inc. employs 41 people — $163K of revenue per employee.
Data provided by Twelve Data
BKYI and its peers
The nearest names by industry and size, scored by the same model — like for like.
Take a look at BKYI’s peer groups, ranked by the model: tech stocks.
Look up any of the roughly 4,300 stocks we score.
The rank is the raw material. Whether the rules would actually own BIO-key International, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Questions about BKYI
What is the BKYI stock price forecast for 2026-2027?
The median 12-month analyst price target for BIO-key International, Inc. is $20. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is BKYI stock a buy right now?
Of the 1 analyst covering BIO-key International, Inc., 1 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks BIO-key International, Inc. 55 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank BKYI?
As at 21 Nov 2026, BIO-key International, Inc. ranks 55 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Accruals (92 of 100).
Will BKYI stock go up?
No one can know that. What the data says: the median 12-month target from 1 analyst is $20, and Ticker Nerd's factor model ranks BIO-key International, Inc. 55 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the BKYI stock forecast for 2030?
No analyst covering BIO-key International, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for BKYI are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $20 to $20 over the next 12 months.
How has BKYI stock performed over the past year?
BIO-key International, Inc. returned -78.5% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
What does BIO-key International, Inc. do?
BIO-key International, Inc. is a biometrics and identity access management company that develops fingerprint authentication and secure access software for organizations. BIO-key International, Inc. offers cloud-based and on-premise identity platforms, including PortalGuard and PortalGuard IDaaS, to support multi-factor authentication, single sign-on, passwordless login, privilege access control, and user provisioning.
About BIO-key International, Inc.
BIO-key International, Inc. is a biometrics and identity access management company that develops fingerprint authentication and secure access software for organizations. BIO-key International, Inc. offers cloud-based and on-premise identity platforms, including PortalGuard and PortalGuard IDaaS, to support multi-factor authentication, single sign-on, passwordless login, privilege access control, and user provisioning. Its product portfolio also includes biometric identity verification tools, civil and large-scale identification systems, mobile authentication applications, and fingerprint readers for enterprise use. The company serves commercial, government, and education customers across industries that require secure workforce, student, citizen, and customer access management. Headquartered in Holmdel, New Jersey, and founded in 1993, BIO-key International, Inc. focuses on combining biometric hardware and software to simplify digital identity security and reduce reliance on traditional credentials.
CEO Mr. Michael W. DePasquale · 41 employees · United States · https://www.bio-key.com